Edimer Pharmaceuticals

📍 United States👥 1 employees💰 Last funded Apr 2013
Biotechnology🌐 edimerpharma.com
Website LinkedIn
Edimer Pharmaceuticals: Working toward improving the health and quality of life of families living with XLHED. Edimer Pharmaceuticals is dedicated to developing EDI200 as a treatment for X-linked Hypohydrotic Ectodermal Dysplasia (XLHED). XLHED is a rare, orphan disease that causes a range of symptoms including lack of sweat glands, poor temperature control, respiratory problems, and hair and tooth malformations. Edimer is led by a team of seasoned biotechnology industry veterans with deep experience in drug development complemented by a strong network of world-class clinical and scientific advisers. The company is based in Cambridge, Massachusetts.
4
Total investors
0
Early stage
0
Mid stage
0
Late stage
—
Founded

Investors

4 investors
All
Early stage
Mid stage
Late stage
Investor geography2 countries
United States
3
Switzerland
1
Investor activity2005–2013 · investors recorded per year
200512011120132
Recent (last 2y)Earlier
Frequently asked questions
Who invested in Edimer Pharmaceuticals?
Edimer Pharmaceuticals has 4 investors on record on gritt.io.
When did Edimer Pharmaceuticals last raise funding?
The most recent investment in Edimer Pharmaceuticals recorded on gritt.io was in April 2013.
What industry is Edimer Pharmaceuticals in?
Edimer Pharmaceuticals operates in Biotechnology. Find similar Biotechnology investors on gritt.io.
Where is Edimer Pharmaceuticals based?
Edimer Pharmaceuticals is headquartered in United States.